Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
- Clinical data showed favorable outcomes with low toxicity rates in high-risk prostate cancer patients
- System demonstrated effectiveness in treating recurrent cancer with mild toxicity
- Strong attendance of 350 healthcare professionals at company symposium indicates market interest
- Treatment requires only 5 sessions, offering convenience and shorter treatment duration
- None.
Insights
Accuray's CyberKnife data shows promising results for prostate cancer in fewer treatment sessions, potentially expanding their addressable market.
The clinical evidence presented at ESTRO 2025 provides meaningful validation for Accuray's CyberKnife System in treating prostate cancer with stereotactic body radiation therapy (SBRT). Two key studies showcase the system's versatility and effectiveness:
The first study examined 262 high-risk prostate cancer patients over age 70 or with severe comorbidities, demonstrating favorable outcomes and low toxicity rates with a 39-month median follow-up. This expands the potential patient population for CyberKnife by confirming its suitability for complex, high-risk cases.
The second study (STARR trial) evaluated the system for recurrent cancer after prostatectomy, reporting only mild toxicity in 51 patients with 16-month median follow-up. The investigators specifically noted the convenience advantage of the shorter treatment duration compared to standard approaches.
The condensed five-session treatment protocol represents a significant efficiency improvement over conventional radiotherapy, which typically requires 20+ sessions over several weeks. This reduction in treatment time offers substantial quality-of-life benefits for patients while potentially increasing throughput for treatment centers.
The symposium's attendance by 350 healthcare professionals indicates strong clinical interest, and the 40+ studies using Accuray technology presented at ESTRO suggests broad investigation across applications. While this ongoing clinical validation is encouraging, it represents incremental progress rather than a transformative development. The retrospective nature of the first study and relatively short follow-up in the second study also warrant consideration when evaluating long-term clinical impact.
More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia
"At this year's ESTRO meeting important analyses of real-world evidence (RWE) underscored the benefits of our unique robotic and helical platforms, reaffirming their use as patients' primary care option or along with other modalities such as surgery, chemotherapy or immunotherapy. Stand out studies focused on the company's CyberKnife System for the treatment of prostate cancer, building on a robust body of clinical data supporting its use and confirming the durability and quality of life after 10 years post-treatment. We're grateful to the clinicians who continue to evaluate our technologies and advance personalized and precise care of patients through the work that they do," said Suzanne Winter, president and CEO of Accuray.
During the meeting, Accuray hosted a symposium titled, "Integrating Advanced Techniques in Genitourinary Radiotherapy: Harmonizing Precision, Personalization, and Efficacy," attended by 350 healthcare professionals. The event featured global thought leaders who spoke on advancements in the treatment of genitourinary indications - prostate, kidney, and bladder cancers - with radiotherapy. Patient care in these areas is dynamic and evolving rapidly, with SBRT now recognized as a safe and effective alternative to conventional treatments for localized prostate cancer and evidence continuing to build for the use of SBRT in salvage prostate treatments.
CyberKnife Platform: Empowering Advances in Prostate Cancer Patient Care
A retrospective analysis titled, "Long-term outcomes and treatment efficacy in high-risk prostate cancer patients treated with stereotactic extreme hypofractionated radiotherapy," reports on 262 men over the age of 70 or with severe comorbidities who were diagnosed with either non-metastatic high-risk or very high-risk prostate cancer and received SBRT delivered with the CyberKnife System in five sessions. With a median follow-up of 39 months, investigators found that treatment with the system offers a promising option with favorable outcomes and low rates of acute and late urogenital (UG) and gastrointestinal (GI) toxicities.
"Early results from a trial on stereotactic salvage radiotherapy for macroscopic prostate bed recurrence after prostatectomy: STARR (NCT05455736)" is a prospective study evaluating the use of stereotactic salvage radiotherapy (SSRT) delivered with the CyberKnife System in five sessions. Androgen deprivation therapy was prohibited during SSRT. An early analysis of 51 patients with a median follow up of 16 months found that the CyberKnife System provides an effective and convenient option with mild toxicity for the treatment of recurrent cancer in the prostate bed following prostatectomy. The study investigators concluded, "Only mild toxicity was reported, underlining the safety of the treatment. Moreover, SSRT may be considered a convenient approach considering the shorter treatment duration if compared to standard approach."
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations related to the Company's products, including CyberKnife System; clinical results; patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 5, 2025, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1 ESTRO 2025 annual congress. https://user-swndwmf.cld.bz/ESTRO-2025-Abstract-Book/2003/
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-showcases-new-long-term-data-on-benefits-of-5-session-radiotherapy-treatment-for-men-with-prostate-cancer-at-estro-2025-302448290.html
SOURCE Accuray Incorporated
FAQ
What were the key findings of Accuray's CyberKnife System studies presented at ESTRO 2025?
How many treatment sessions are required for ARAY's CyberKnife prostate cancer treatment?
What was the size of the patient study group in Accuray's retrospective analysis?
How many healthcare professionals attended Accuray's ESTRO 2025 symposium?
What was the median follow-up period for ARAY's CyberKnife prostate cancer study?
